Welcome to our dedicated page for Treatment.com AI news (Ticker: TREIF), a resource for investors and traders seeking the latest updates and insights on Treatment.com AI stock.
The TREIF news page aggregates coverage related to Rocket Doctor AI Inc., a healthcare technology company focused on physician-built, AI-powered digital health platforms. Here you can follow announcements about Rocket Doctor AI’s virtual care programs, payer relationships, technology developments, and market activities connected to its AI-driven clinical decision support and digital marketplace.
Rocket Doctor AI’s news frequently highlights the role of its Global Library of Medicine (GLM), a clinically validated decision support system, and its AI-powered platform operated through Rocket Doctor Inc. Updates often describe how over 300 medical doctors have used the platform to deliver hundreds of thousands of virtual or hybrid patient visits, supported by proprietary software, large language models, and connected medical devices.
Investors and observers can expect news items on topics such as virtual care initiatives in Canada and the United States, programs aimed at underserved, rural, and remote communities, and arrangements that support patients on Medicaid and Medicare. Releases also cover partnerships with pharmacies, community organizations, and health systems that integrate Rocket Doctor’s virtual care tools into local settings.
Because Rocket Doctor AI operates within digital health and AI in healthcare, company news often touches on the expansion of virtual care offerings, integration of diagnostic devices, and efforts to reduce administrative burdens for clinicians. This page provides a centralized view of these developments, allowing readers to track how the company’s AI-powered technology and marketplace are being applied across different regions and care settings. Bookmark this page to review new Rocket Doctor AI Inc. (TREIF) news as it becomes available on Stock Titan.
Treatment.com International Inc. (CSE: TRUE; OTC: TREIF) announced a non-brokered private placement to raise up to $1,250,000 through unsecured convertible debentures. Each debenture will have an 8% interest rate, maturing in 36 months, and is convertible into units at a price of $0.41. Investors will receive interest payments monthly, with the option to be paid in company units. The funds will be used for general working capital. The units issued upon conversion will be subject to a 12-month hold period.
Treatment.com International Inc. (CSE: TRUE; OTC: TREIF) launched its Treatment Digital Health App on the Google Play Store, expanding access to its innovative AI-driven healthcare technology. The app, initially available on the Apple App Store, is designed to assist users in making informed health decisions with advanced medical knowledge. The launch aligns with the increasing demand for credible health information, particularly during the COVID era. CEO John Fraser and Chief Strategy Officer Dr. Paul A. Markham emphasized the app's groundbreaking capabilities compared to typical online health searches.
Treatment.com International Inc. (CSE: TRUE; OTC: TREIF) has officially launched the Treatment Digital Health App, now available on the Apple App Store. This innovative app utilizes a next-generation AI platform, offering users advanced symptom assessment tools built by a team of medical professionals and engineers. The app's technology is designed to provide accurate health insights, leveraging the Global Library of Medicine (GLM) for up-to-date medical information. The CEO emphasizes the app's role in enhancing healthcare decision-making during the pandemic, aiming for improved individual health outcomes.
Treatment.com International (CSE: TRUE, OTC: TREIF) has announced a research project agreement with the University of Minnesota to add over 220 dermatologic diseases to its AI engine, the Global Library of Medicine (GLM). This collaboration aims to enhance the accuracy of the GLM, supporting the upcoming Treatment Mobile app release. According to Treatment's Chief Medical Officer, the partnership will leverage the University’s expertise to improve skin disease descriptions, thereby aiming to better health outcomes globally. The Treatment Mobile app and intelligent assistant are set to launch in selected North American clinics in 2022.
Treatment.com International has announced the first sale of its Treatment Primary Care Module, an AI-powered solution designed to enhance patient-doctor interactions in medical clinics. This innovative system allows for efficient pre-interviewing of patients, leading to improved diagnosis and treatment recommendations. The partnership with Dr. Rob Scott's clinic signifies a transformative step for AI in healthcare. The company aims to roll out more products in the future, enhancing its presence in the healthcare technology sector.
Treatment.com International Inc. (CSE: TRUE; OTC: TREIF) has announced the beta launch of its Treatment Digital Health App, driven by a proprietary AI platform. This app aims to provide up-to-date health information to users, enhancing decision-making during ongoing health crises like COVID. Built by a global team of doctors, the app is expected to personalize health recommendations for users. The beta is exclusive, with a broader U.S. launch planned for the new year. Treatment.com focuses on integrating advanced medical protocols into user-friendly applications.
Treatment.com International Inc. (CSE: TRUE, OTC: TREIF) has announced the expansion of its Global Library of Medicine (GLM) with new members from Belgium. This initiative enhances the world’s most advanced medical database, now comprising over 50 doctors across four continents. The GLM aims to improve patient safety and healthcare outcomes through its extensive knowledge on complex diseases and risk factors. Treatment.com focuses on utilizing AI to provide personalized health insights and recommendations via its intelligent mobile app.
Treatment.com International (CSE: TRUE, OTC: TREIF) is launching a revolutionary global 'Medical Metaverse' aimed at enhancing healthcare delivery through AI-driven solutions. This initiative will integrate a Global Library of Medicine with AR and VR technologies, facilitating collaboration among medical professionals worldwide. The company envisions improved medical education and clinical decision support through immersive environments, which could redefine global telehealth. Management believes this innovative approach will attract diverse healthcare stakeholders and enhance patient care.
Treatment.com International Inc. (CSE: TRUE • OTC: TREIF) has announced a new healthcare technology initiative aimed at enhancing physician participation in its Global Library of Medicine (GLM). This initiative will implement a value-based rewards system utilizing convertible, non-fungible tokens (NFTs) for medical professionals who contribute to the GLM. The software platform consists of three layers: clinical, technical, and fiscal, designed to streamline the fiscal exchange as healthcare becomes more digital. This approach is expected to improve payment efficiency for contributors and leverage blockchain technology.
Treatment.com International Inc. (CSE: TRUE) has announced the development of an AI health assistant named Cara, supported by their proprietary Global Library of Medicine and AI engine. This mobile app aims to enhance consumer healthcare experiences through a friendly and approachable interface. After eight months of testing, Treatment emphasized the importance of a supportive healthcare journey. The launch of Cara marks a significant step in expanding their technology's reach, aiming to disrupt traditional healthcare with personalized insights and recommendations.